Group 1 - The core viewpoint of the article highlights the successful debut of Precision Medical-B (02675) on the stock market, with a significant opening increase of 36.45% [1] - The company priced its shares at HKD 43.24, issuing a total of 27.72 million shares, resulting in a net proceeds of HKD 1.117 billion [1] - As of the report, the stock was trading at HKD 59, with a transaction volume of HKD 188 million [1] Group 2 - Precision Medical is recognized as an advanced surgical robot company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - According to Frost & Sullivan, the company is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - Financial projections indicate revenues of approximately HKD 48.04 million, HKD 160 million, and HKD 150 million for the years 2023, 2024, and the first half of 2025, respectively, with expected losses of around HKD 213 million, HKD 219 million, and HKD 89.087 million [1] Group 3 - According to Founder Securities, the global IPO of Precision Medical has attracted diverse and global cornerstone investors, reigniting capital interest in the laparoscopic robot sector [2] - The current penetration rate of laparoscopic surgical robots in China is less than 1%, significantly lower than the 21.9% in the United States, indicating substantial room for growth in domestic market share [2] - The market is predominantly led by the Da Vinci system, which holds over 40% of the market share, suggesting opportunities for increased domestic production [2]